Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Max Heckler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3213-5068; OpenAlex author ID A5025194090. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 3 papers

Papers 11

  1. Dual mTORC1/2 and Scd1 inhibition uncovers a therapeutic vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41388-026-04026-x↗
  2. Tumor Location and Preoperative Biliary Stenting Shape Gut Microbiome Diversity in Pancreatic Cancer. Co-author DOI 10.3390/cancers18162617↗
  3. Preoperative biliary stenting is associated with functional dysbiosis and impaired bile acid metabolism in pancreatic cancer - Impact of preoperative biliary s… Co-author DOI 10.64898/2026.05.19.719953↗
  4. Influence of beta-blockers and other non-cancer drugs on outcomes after pancreatic cancer resection. Co-author DOI 10.1093/bjs/znac434↗
  5. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis. First author DOI 10.1245/s10434-022-12569-y↗
  6. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  7. Prospective trial to evaluate the prognostic value of different nutritional assessment scores for survival in pancreatic ductal adenocarcinoma (NURIMAS Pancrea… Co-author DOI 10.1002/jcsm.12796↗
  8. Surgery for locally advanced pancreatic ductal adenocarcinoma-is it only about the vessels? Co-author DOI 10.21037/jgo-20-313↗
  9. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Co-author DOI 10.1002/bjs.11295↗
  10. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. First author DOI 10.1016/j.ejso.2019.03.039↗
  11. Unmasking Pancreatic Cancer: Epitope Spreading After Single Antigen Chimeric Antigen Receptor T-Cell Therapy in a Human Phase I Trial. Co-author DOI 10.1053/j.gastro.2018.06.023↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thilo Hackert · 7 shared papers, 2019–2023 · strength 1.12
  2. Thomas P. Hank · 5 shared papers, 2021–2026 · strength 0.93
  3. Markus Wolfgang Büchler · 6 shared papers, 2019–2023 · strength 0.84
  4. Franco Fortunato · 3 shared papers, 2026 · strength 0.69
  5. Christoph W. Michalski · 3 shared papers, 2026 · strength 0.69
  6. Ulla Klaiber · 5 shared papers, 2019–2023 · strength 0.64
  7. Ingmar Florin Rompen · 2 shared papers, 2026 · strength 0.47
  8. Marionna Cathomas · 2 shared papers, 2026 · strength 0.47
  9. Jonathan M. Harnoss · 2 shared papers, 2026 · strength 0.47
  10. Rogier Aäron Gaiser · 2 shared papers, 2026 · strength 0.47
  11. Bo Kong · 2 shared papers, 2026 · strength 0.47
  12. Peer Bork B · 2 shared papers, 2026 · strength 0.47
  13. Martin Loos · 2 shared papers, 2026 · strength 0.45
  14. Pascal Probst · 3 shared papers, 2019–2023 · strength 0.43
  15. Masayuki Tanaka · 3 shared papers, 2019–2023 · strength 0.40
  16. André L. Mihaljević · 3 shared papers, 2019–2023 · strength 0.40
  17. Ulrike Heger · 3 shared papers, 2019–2023 · strength 0.40
  18. Felix Jakob Hüttner · 2 shared papers, 2021–2023 · strength 0.33
  19. Markus K. Diener · 2 shared papers, 2021–2023 · strength 0.33
  20. Chao Fang · 1 shared paper, 2026 · strength 0.22
  21. Bo Kong · 1 shared paper, 2026 · strength 0.22
  22. Helmut Friess · 1 shared paper, 2026 · strength 0.22
  23. İhsan Ekin Demir · 1 shared paper, 2026 · strength 0.22
  24. Ingrid Herr · 1 shared paper, 2026 · strength 0.22
  25. Shigenori Ei · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.